SFA
SUPN icon

Sequoia Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Sequoia Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
+4,099
New +$209K ﹤0.01% 1760

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sequoia Financial Advisors's SUPN Position: Q1 2026 in Review

Sequoia Financial Advisors opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2026: 4,099 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1760 among its holdings.

327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Sequoia Financial Advisors held 4,099 shares of Supernus Pharmaceuticals worth $212K as of Q1 2026.
  • Supernus Pharmaceuticals was a new Sequoia Financial Advisors position in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Sequoia Financial Advisors's portfolio in Q1 2026, its #1760 holding.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Sequoia Financial Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.